Hypertrophic cardiomyopathy: Tools for identifying risk and alleviating symptoms

Postgraduate Medicine

Volumn 107, Issue 7, 2000, Pages 127-140

  DeLuca, Michael ^a   Tak, Tahir ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DISOPYRAMIDE PHOSPHATE; MEXILETINE; QUINIDINE; VERAPAMIL;

ARTICLE; CLINICAL FEATURE; DISEASE COURSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EXERCISE TEST; FAMILY COUNSELING; HEART SURGERY; HYPERTROPHIC CARDIOMYOPATHY; INCIDENCE; PHONOCARDIOGRAPHY; PHYSICAL EXAMINATION; RISK FACTOR; SUDDEN DEATH; THORAX RADIOGRAPHY; TREATMENT PLANNING;

EID: 0033920345     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2000.06.1126     Document Type: Article

References (21)

1. Levine RA. Echocardiographic assessment of the cardiomyopathies. In: Weyman AE. Principles and practice of echocardiography. 2d ed. Philadelphia: Lea & Febinger, 1994:781-804
2. Marian AJ, Roberts R. Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation 1995;92(5): 1336-47
3. Braunwald E. Valvular heart disease. In: Braunwald E. Heart disease: a text book of cardiovascular medicine. 5th ed. Philadelphia: Saunders, 1997:1007-77
4. Nishimura RA, Giuliani ER, Brandenburg RO, et al. Hypertrophic cardiomyopathy. In: Giuliani ER, Gersh BJ, McGoon MG, et al. Mayo Clinic practice of cardiology. 3d ed. St Louis: Mosby, 1996:689-711
5. Oh JK, Seward JB, Tajik AJ. Cardio-myopathies. In: Oh JK, Seward JB, Tajik AJ. The echo manual. 2d ed. Philadelphia: Lippincott-Raven, 1999:156-63
6. Maron BJ, Thompson PD, Puffer JC, et al. Cardiovascular preparticipation screening of competitive athletes: a statement for health professionals from the Sudden Death Committee (clinical cardiology) and Congenital Cardiac Defects Committee (cardiovascular disease in the young), American Heart Association. Circulation 1996;94(4):850-6
7. Yu B, French JA, Jeremy RW, et al. Counselling issues in familial hypertrophic cardiomyopathy. J Med Genet 1998;35(3): 183-8
8. Slade AK, Camm AJ. Risk assessment and prevention of sudden cardiac death in hypertrophic cardiomyopathy. Arch Mal Coeur Vaiss 1996;89 Spec No 1:37-49
9. Fananapazir L, McAreavey D. Hypertrophic cardiomyopathy: evaluation and treatment of patients at high risk for sudden death. Pacing Clin Electrophysiol 1997:20(2 Pt 2):478-501
10. Marian AJ. Sudden cardiac death in patients with hypertrophic cardiomyopathy: from bench to bedside with an emphasis on genetic markers. Clin Cardiol 1995; 18(4):189-98
11. Spirito P, Seidman CD, McKenna WJ, et al. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336(11):775-85
12. Maron BJ. Hypertrophic cardiomyopathy. Lancet 1997;350(9071):127-33
13. Louie EK, Edwards LC 3d. Hypertrophic cardiomyopathy. Prog Cardiovasc Dis 1994;36(4):275-308
14. Zhu DW, Sun H, Hill R, et al. The value of electrophysiology study and prophylactic implantation of cardioverter defibrillator in patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 1998;21(1 Pt 2):299-302
15. Kuck KH. Arrhythmias in hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 1997;20(10 Pt 2):2706-13
16. Task Force on Practice Guidelines Committee on Management of Patients with Valvular Heart Disease. ACC/AHA guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association. J Am Coll Cardiol 1998;32(5):1486-588
17. Kappenberger L, Linde C, Daubert C, et al. Pacing in hypertrophic obstructive cardiomyopathy: a randomized crossover study. Eur Heart J 1997;18(8):1249-56
18. Nishimura RA, Trusty JM, Hayes DL, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol 1997;29(2):435-41
19. Fananapazir L, McAreavey D. Therapeutic options in patients with obstructive hypertrophic cardiomyopathy and severe drug-refractory symptoms. (Editorial) J Am Coll Cardiol 1998;31(2): 259-64
20. Seggewiss H, Gleichmann U, Faber L, et al. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 1998;31(2):252-8
21. Hasegawa K, Fujiwara H, Doyama K, et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 1993;88(2):372-80